Tag: revenues

Press release
Paris, 8 June 2026

BASKING RIDGE, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- All customers with telephone numbers with the 347/718/917/929 area codes should be aware of the introduction of the new 465 area code. Beginning June 18, 2026, customers ordering new telephone lines or services in the boroughs of the Bronx, Brooklyn, Queens, Staten Island as well as the Marble Hill section of Manhattan may be assigned numbers using the new 465 area code.

RENO, Nev., June 08, 2026 (GLOBE NEWSWIRE) -- Ormat Technologies, Inc. (NYSE: ORA) (the “Company” or “Ormat”), a leading geothermal and renewable energy company and the only vertically integrated designer, builder, owner, and operator of geothermal facilities in the world, today announced the Ormega100, a revolutionary new surface power generation unit engineered to deliver higher output than any other binary solution currently on the market. The Ormega100 marks an accelerated opportunity to commercialize and scale its Enhanced Geothermal System (EGS) developments, connecting subsurface development with surface power generation at an accelerated pace.

Basel, June 8th, 2026 – Novartis will present data from 10 abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026, spanning Rhapsido^®  (remibrutinib) clinical trial results and real-world evidence on patient burden and treatment experience. Highlights include two late-breaking oral presentations; the Phase III RemIND trial for Rhapsido in chronic inducible urticaria (CIndU) and extension data from the Phase IIIb REMIXED trial in chronic spontaneous urticaria (CSU).

“The Rhapsido presentations at EAACI 2026 expand our understanding of BTK inhibition across multiple immune-mediated diseases and provide evidence of its potential to make a meaningful impact for patients who continue to face significant burden and limited treatment options,” said Angelika Jahreis, Global Head, Immunology Development, Novartis. “Novartis will present Rhapsido data from a long-term extension trial in chronic spontaneous urticaria, Phase III data in three types of chronic inducible urticaria, and early Phase II dose-response analysis for food allergy – together providing scientific evidence for its impact across numerous diseases.”

Abstracts accepted by EAACI include: 

NEW YORK, June 07, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Babcock & Wilcox Enterprises, Inc. (“B&W”) (NYSE: BW) between November 5, 2025 and March 11, 2026, inclusive (the “Class Period”), of the important June 15, 2026 lead plaintiff deadline.

Press release
Paris, 6 June 2026

Press release
Paris, 6 June 2026